Artelo Biosciences entered into R&D partnership with Syngene and Aptus

| By | Cancer Drugs, Drug Development, R&D

Artelo Biosciences, a biopharmaceutical company focused on the development of therapeutic treatments that modulate the endocannabinoid system, entered into a global research and development partnership with Syngene International Ltd. (Syngene), an India-based integrated discovery-development service provider, through its wholly-owned subsidiary, Trinity Research and Development Limited, and Aptus Clinical Ltd. (Aptus), a specialist UK-based Clinical Contract Research Organization with particular expertise in oncology, rare diseases and advanced therapies. 

The partnership will focus on supporting the drug discovery and clinical development of ART27.13, Artelo’s Phase 2 ready, high-potency dual cannabinoid agonist, in oncology.

As part of the agreement, Syngene will be the discovery and development partner providing a pre-clinical data package to support the advancement of ART27.13 for anti-cancer indications.

Aptus Clinical will develop and design an anti-cancer clinical study that is scientifically credible, ethically acceptable and operationally deliverable. It will also provide clinical development and regulatory expertise to the partnership.

Previously, Artelo established its UK subsidiary at the Alderley Park BioHub in Cheshire.

Aptus Clinical Limited (UK) is a contract clinical research organization that specializes in the design, conduct and delivery of early phase clinical studies with a particular focus in oncology, rare diseases, cell and gene therapies. Projects are delivered by a team of highly experienced drug development experts utilizing their extensive network of academic links.

Syngene International (India) is a global integrated discovery and development service provider for small and large molecules, Antibody-Drug Conjugates and Oligonucleotides. Its clientele of over 300 clients span the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemicals industries and include market leaders like Bristol-Myers Squib, Baxter, Amgen, GSK, Zoetis, Merck KGaA and Herbalife. Syngene’s innovation driven culture, strong team of over 3500 scientists and world-class research and manufacturing infrastructure help its clients improve R&D productivity while reducing the development time and cost.

Artelo Biosciences (San Diego, USA) is dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including cancer, pain, and inflammation.